GlassScriptPhysician profile
Rachenetta V Stimage
NPI 1861601049
$2,862.90
in general payments reported to CMS, 2019-2025
15 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $201 · 2020: $139 · 2021: $39.40 · 2022: $80.36 · 2023: $242 · 2024: $72.48 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,000 · Food and Beverage: $403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,000.00 |
| Food and Beverage | $403.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $2,000.00 | 2025 | |
| Abbvie INC. | $359.20 | 2019-2024 | |
| Astellas Pharma US INC | $126.11 | 2023-2025 | Veozah |
| Pacira Pharmaceuticals Incorporated | $121.82 | 2023 | Exparel |
| Mayne Pharma Commercial LLC | $45.45 | 2023-2025 | |
| Applied Medical Resources Corporation | $39.40 | 2021 | |
| Shield Therapeutics INC | $36.66 | 2024 | |
| Organon LLC | $23.13 | 2025 | Nexplanon |
| Medline Industries LP | $22.59 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.30 | 2019 | |
| Exeltis, USA INC. | $17.17 | 2024 | Slynd |
| Coopersurgical, INC. | $14.16 | 2022 | |
| Sage Therapeutics, LLC | $14.11 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $14.00 | 2020 | |
| Merck Sharp & Dohme LLC | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachenetta Stimage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.